Maekawa T, Fujii H, Shizumi Y, Ebisui S, Horishi M, Suyama Y, Miyoshi M, Horiike S
3rd Dept. of Intern. Med., Kyoto 1st Red Cross Hospital.
Gan No Rinsho. 1988 Dec;34(15):2109-13.
In April, 1985, a 60-year-old Japanese male was diagnosed as having refractory anemia with an excess of blasts (RAEB). He thus was treated solely with blood transfusions until June, 1986, when a new diagnosis revealed that his illness had been transformed into acute myelogenous leukemia (M2). Chromosome analysis at the initial diagnosis had revealed a normal male karyotype. When the subsequent diagnosis of AML was made, however, a chromosomal abnormality [46, XY, -20, +der (20) t (?8;20) (q22;p13)] was detected. Myelodysplastic syndrome (MDS) in patients evidencing a karyotypic alteration from the initial karyotypic findings progresses in severity that includes overt leukemia, and results in a shorter survival than in patients who show no further karyotypic changes. Therefore, the prognosis of patients with MDS can be predicted more accurately by subsequently reanalyzing their chromosomes after the initial analysis, as well as by examining their peripheral blood/counts, and by monitoring bone marrow cytology.
1985年4月,一名60岁的日本男性被诊断为伴有过多原始细胞的难治性贫血(RAEB)。因此,在1986年6月之前他仅接受输血治疗,当时新的诊断显示他的病情已转变为急性髓性白血病(M2)。初始诊断时的染色体分析显示为正常男性核型。然而,在随后诊断为AML时,检测到一种染色体异常[46, XY, -20, +der (20) t (?8;20) (q22;p13)]。与初始核型结果相比出现核型改变的患者,其骨髓增生异常综合征(MDS)病情会加重,包括发展为明显的白血病,并且生存期比未出现进一步核型改变的患者短。因此,通过在初始分析后对患者染色体进行再次分析,以及检查其外周血细胞计数和监测骨髓细胞学,可以更准确地预测MDS患者的预后。